
During the Health System Executive Summit, Candy Tsourounis, PharmD, and Elise Wozniak, PharmD got candid about the barriers and financial risk surrounding this innovative therapy.
NME: 5-alpha reductase inhibitor for treatmentof benign prostatic hyperplasia






